SENZIME AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.82 SEK | +13.67% |
|
+14.43% | -8.21% |
| Apr. 24 | Senzime Announces Major Public Tender Contract by the US Department of Veterans Affairs | CI |
| Apr. 10 | Senzime AB Secures Multiple Top-Rated US Hospital Deals | CI |
| Sales 2023 | 35.75M 3.27M | Sales 2024 * | 79.8M 7.29M | Capitalization | 816M 74.62M |
|---|---|---|---|---|---|
| Net income 2023 | -141M -12.89M | Net income 2024 * | -106M -9.69M | EV / Sales 2023 | 21 x |
| Net cash position 2023 | 140M 12.76M | Net cash position 2024 * | 43M 3.93M | EV / Sales 2024 * | 9.69 x |
| P/E ratio 2023 |
-5.12
x | P/E ratio 2024 * |
-7.66
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 33.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Senzime AB
More press releases
| 1 day | +13.67% | ||
| 1 week | +14.43% | ||
| Current month | +10.00% | ||
| 1 month | +13.67% | ||
| 3 months | -13.23% | ||
| 6 months | +4.60% | ||
| Current year | -8.21% |
1 week
5.76
6.82
1 month
5.686.82
Current year
5.688.46
1 year
2.618.46
3 years
2.6126.00
5 years
2.6128.50
10 years
2.6128.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 15-12-31 | |
| Director of Finance/CFO | 54 | 21-12-31 | |
Fredrik Norrby
CTO | Chief Tech/Sci/R&D Officer | 48 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 15-12-31 | |
| Director/Board Member | 71 | 22-12-31 | |
Jenny Freeman
BRD | Director/Board Member | 70 | 21-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.82 | +13.67% | 420,536 |
| 24-04-25 | 6 | -3.69% | 122,074 |
| 24-04-24 | 6.23 | +5.24% | 247,264 |
| 24-04-23 | 5.92 | -0.34% | 19,514 |
| 24-04-22 | 5.94 | -0.34% | 95,133 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotes
Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.21% | 65.86M | |
| -2.31% | 185B | |
| -3.20% | 105B | |
| -5.04% | 66.59B | |
| +0.20% | 54.66B | |
| +17.29% | 47.78B | |
| +4.06% | 41.26B | |
| +2.36% | 26.95B | |
| +2.07% | 26.37B | |
| +12.96% | 24.8B |
- Stock Market
- Equities
- SEZI Stock
